Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

Abstract: Treating Sonic Hedgehog-Associated Medulloblastoma comprises inhibiting the synthesis or biologic activity of leukotrienes that drive Nestin expression in cancerous or precancerous granule neuron precursors and that further drive growth and proliferation of medulloblastoma cells through Nestin-mediated aberrant Sonic Hedgehog signaling.

Abstract: The invention provides aromatherapy devices that may be used to break a capsule containing a desired aromatic liquid, and then control the release of the aroma as the volatile aromatic liquid evaporates. The devices may be used, for example, in aromatherapy, including to control nausea or to mask unpleasant scents.

Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.

Abstract: A method and system for scheduling, tracking, recording, and monitoring of patients' usage of an infusion room, along with various tools to analyze the infusion room activity, to thereby improve usage of the infusion room, and improve patient satisfaction relating to their infusion room experience, is disclosed. The inventive methods and systems use real-time computer processors, software, and distributed sensors to monitor, record, analyze, and graphically display relevant infusion room chair status, patient status, and patient medical condition while in the infusion room. In preferred embodiments, the inventive methods and systems provide real-time input capability for medical personnel, and real-time automatic data output for use by or to prompt medical personnel. The inventive methods and systems are capable of recording activity of the infusion room to permit later analysis, modeling, and simulation to allow for improvements in infusion room efficiencies and patient satisfaction.

Abstract: Methods for treating tumors comprising cells expressing the vitamin D receptor are provided, and comprise inhibiting the expression or the biologic activity of the vitamin D receptor in the tumor cells, and/or inhibiting the expression or the biologic activity of a constituent of the vitamin D receptor signaling pathway in the tumor cells, and administering to the tumor cells an effective amount of gemcitabine.

Abstract: Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.

Abstract: Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling.

Abstract: Systems and methods for diagnosing or characterizing a predisposition to colon cancer are provided. Cell nuclei may be evaluated for the presence or quantity of gamma-H2AX foci. Nucleic acids may be evaluated for the presence, type, or quantity of genomic instability or surrogates of dsDNA breaks such as ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), and Tumor suppressor p53-binding protein 1 (53BP1) in gamma-H2AX foci. Nucleic acids comprising a germline nucleic acid sequence of the ERCC6, WRN, TERT, and FAAP100 genes may be sequenced or probed to determine if the nucleic acid sequence includes one or more alterations that cause genomic instability, dsDNA breaks, or gamma-H2AX foci or otherwise predispose a subject to develop colon cancer.

Abstract: An imaging cassette. The cassette includes a top frame, a bottom frame, and one or more of a front wall, back wall, or plurality of posts, and defines a chamber for holding an animal in a desired position for analysis in a fluorescence molecular tomography imager and a vertical bore magnetic resonance imager.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer, including cancers of the BAP1 cancer syndrome, are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 (BAP1) are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.

Abstract: Methods for inhibiting the motility or proliferation of premalignant and malignant cells are provided. Methods for treating a malignancy of the head and neck and for treating a malignancy of the lung are also provided.